查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1599297

病毒载体市场：按类型、疾病、应用和最终用户划分 - 2025-2030 年全球预测

Viral Vectors Market by Type (Adeno-associated Viral Vectors, Adenoviral Vectors, Retroviral Vectors), Disease (Cancers, Genetic Disorders, Infectious Diseases), Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

病毒载体市场2023年估值为16.6亿美元，预计2024年将达18.8亿美元，复合年增长率为14.09%，预计2030年将达到41.8亿美元。

作为 360iResearch 的市场研究分析师，对病毒载体市场的调查揭示了其作为基因治疗、疫苗开发和分子生物学中用于将遗传物质传递到细胞中的重要工具的范围。对病毒载体的需求源于它们在重要的医疗保健解决方案中的应用，包括遗传疾病、感染疾病和癌症的治疗，因为它们能够促进有效的基因转移。最终用途范围主要包括製药和生物技术公司、研究机构和专注于推进基因研究和开发新疗法的临床实验室。主要成长动力包括研发投资的增加、基因治疗技术的进步以及需要创新治疗的慢性病盛行率上升。此外，载体设计和递送系统的技术进步为提高安全性和效率提供了潜在的机会，这对于充分发挥基因治疗的潜力至关重要。然而，市场成长面临製造成本高、法律规范复杂以及患者潜在免疫抗原性等挑战。创新应着重于改进载体传递机制、最大限度地减少副作用和开发可扩展的製造流程。此外，鼓励与学术和临床研究机构合作，以促进开发具有成本效益和有针对性的载体解决方案。此外，对非病毒传递方法的进一步探索可能会弥补当前病毒载体带来的局限性，并为更安全、更有效的治疗铺平道路。市场竞争激烈，不断的创新和合作伙伴关係塑造着格局，凸显了对策略性研发投资和敏捷的打入市场策略的需求。为了利用快速成长的商机，相关人员正在专注于将先进的分析和机器学习工具整合到研究工作中，以提高治疗开发的精确度并增强病毒载体应用的扩充性和采用率。

主要市场统计
基准年[2023] 16.6亿美元
预测年份 [2024] 18.8亿美元
预测年份 [2030] 41.8亿美元
复合年增长率（%） 14.09%

市场动态：揭示快速发展的病毒载体市场的关键市场洞察

供需的动态交互作用正在改变病毒载体市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 增加针对各种感染疾病和病毒的疫苗产量
    • 目标疾病和疾病的盛行率增加
    • 细胞和基因治疗的政府倡议
  • 市场限制因素
    • 基因和细胞治疗成本上升
  • 市场机会
    • 罕见疾病治疗的持续研究和开发
    • 大型合约开发/製造公司的投资
  • 市场挑战
    • 插入突变和免疫反应的风险

波特五力：驾驭病毒载体市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解病毒载体市场的外部影响

外部宏观环境因素在塑造病毒载体市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解病毒载体市场的竞争状况

对病毒载体市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵病毒载体市场供应商绩效评估

FPNV定位矩阵是评估病毒载体市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了病毒载体市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对病毒载体市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 增加针对各种感染疾病和病毒的疫苗产量
      • 目标疾病和疾病的盛行率增加
      • 政府关于细胞和基因治疗的倡议
    • 抑制因素
      • 基因/细胞治疗费用高
    • 机会
      • 罕见疾病治疗的持续研究和开发
      • 大型开发和受託製造组织的投资
    • 任务
      • 插入突变和免疫反应的风险
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章病毒载体市场：依类型

  • 腺结合病毒载体
  • 腺病毒载体
  • 逆转录病毒载体

第七章病毒载体市场：依疾病分类

  • 癌症
  • 遗传疾病
  • 感染疾病

第八章病毒载体市场：依应用分类

  • 基因治疗
  • 疫苗学

第九章病毒载体市场：依最终用户分类

  • 製药和生物製药公司
  • 调查机构

第10章美洲病毒载体市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区病毒载体市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的病毒载体市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • ABL Inc.
  • Batavia Biosciences BV
  • Bio-Rad Laboratories, Inc.
  • BioNTech IMFS GmbH
  • Biovian Oy
  • Cevec Pharmaceuticals GmbH
  • Creative Biogene
  • FUJIFILM Diosynth Biotechnologies USA, Inc.
  • GeneOne Life Science, Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • Sirion-Biotech GmbH
  • Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-957C47F9405B

The Viral Vectors Market was valued at USD 1.66 billion in 2023, expected to reach USD 1.88 billion in 2024, and is projected to grow at a CAGR of 14.09%, to USD 4.18 billion by 2030.

As a Market Research Analyst at 360iResearch, the exploration of the viral vectors market uncovers its scope as integral tools used in gene therapy, vaccine development, and molecular biology to deliver genetic material into cells. The necessity of viral vectors stems from their application in critical healthcare solutions, including the treatment of genetic disorders, infectious diseases, and cancers, owing to their ability to facilitate efficient gene transfer. End-use scope primarily encompasses pharmaceutical and biotechnology companies, research institutions, and clinical laboratories focused on advancing genetic research and developing novel therapeutics. Key growth drivers include increasing research and development investments, advancements in gene therapy techniques, and rising prevalence of chronic diseases demanding innovative treatments. Furthermore, technological advancements in vector design and delivery systems open potential opportunities for enhancement in safety and efficiency, vital for harnessing the full potential of gene therapies. Nevertheless, market growth faces challenges such as high production costs, complex regulatory frameworks, and potential immunogenicity in patients. Innovations should focus on improving vector delivery mechanisms, minimizing adverse effects, and developing scalable manufacturing processes. Moreover, collaborations with academic and clinical research institutions are recommended to drive the development of cost-effective and targeted vector solutions. Further exploration into non-viral delivery methods might also bridge the limitations posed by current viral vectors, paving the way for safer and more efficient therapies. The nature of the market is intensely competitive, with continuous innovations and partnerships shaping its landscape, thus emphasizing the need for strategic R&D investments and agile market entry strategies. To capitalize on the burgeoning opportunities, stakeholders should focus on integrating advanced analytics and machine learning tools in their research efforts, enabling precision in therapeutic development and enhancing the scalability and adoption of viral vector applications.

KEY MARKET STATISTICS
Base Year [2023] USD 1.66 billion
Estimated Year [2024] USD 1.88 billion
Forecast Year [2030] USD 4.18 billion
CAGR (%) 14.09%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Viral Vectors Market

The Viral Vectors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing vaccine production for various infections and viruses
    • Growing prevalence of target ailments and diseases
    • Government initiatives for cell and gene therapy treatments
  • Market Restraints
    • High cost of gene & cell therapy treatments
  • Market Opportunities
    • Ongoing research and development in rare disease treatments
    • Investments by large contract development and manufacturing organizations
  • Market Challenges
    • Risk of insertional mutagenesis and immune response

Porter's Five Forces: A Strategic Tool for Navigating the Viral Vectors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Viral Vectors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Viral Vectors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Viral Vectors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Viral Vectors Market

A detailed market share analysis in the Viral Vectors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Viral Vectors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Viral Vectors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Viral Vectors Market

A strategic analysis of the Viral Vectors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Viral Vectors Market, highlighting leading vendors and their innovative profiles. These include ABL Inc., Batavia Biosciences B.V., Bio-Rad Laboratories, Inc., BioNTech IMFS GmbH, Biovian Oy, Cevec Pharmaceuticals GmbH, Creative Biogene, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., GeneOne Life Science, Inc., Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Sirion-Biotech GmbH, Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Viral Vectors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Adeno-associated Viral Vectors, Adenoviral Vectors, and Retroviral Vectors.
  • Based on Disease, market is studied across Cancers, Genetic Disorders, and Infectious Diseases.
  • Based on Application, market is studied across Gene Therapy and Vaccinology.
  • Based on End User, market is studied across Pharmaceutical & Biopharmaceutical Companies and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing vaccine production for various infections and viruses
      • 5.1.1.2. Growing prevalence of target ailments and diseases
      • 5.1.1.3. Government initiatives for cell and gene therapy treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of gene & cell therapy treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development in rare disease treatments
      • 5.1.3.2. Investments by large contract development and manufacturing organizations
    • 5.1.4. Challenges
      • 5.1.4.1. Risk of insertional mutagenesis and immune response
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Viral Vectors Market, by Type

  • 6.1. Introduction
  • 6.2. Adeno-associated Viral Vectors
  • 6.3. Adenoviral Vectors
  • 6.4. Retroviral Vectors

7. Viral Vectors Market, by Disease

  • 7.1. Introduction
  • 7.2. Cancers
  • 7.3. Genetic Disorders
  • 7.4. Infectious Diseases

8. Viral Vectors Market, by Application

  • 8.1. Introduction
  • 8.2. Gene Therapy
  • 8.3. Vaccinology

9. Viral Vectors Market, by End User

  • 9.1. Introduction
  • 9.2. Pharmaceutical & Biopharmaceutical Companies
  • 9.3. Research Institutes

10. Americas Viral Vectors Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Viral Vectors Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Viral Vectors Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ABL Inc.
  • 2. Batavia Biosciences B.V.
  • 3. Bio-Rad Laboratories, Inc.
  • 4. BioNTech IMFS GmbH
  • 5. Biovian Oy
  • 6. Cevec Pharmaceuticals GmbH
  • 7. Creative Biogene
  • 8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 9. GeneOne Life Science, Inc.
  • 10. Lonza Group Ltd.
  • 11. Merck KGaA
  • 12. Miltenyi Biotec B.V. & Co. KG
  • 13. Sirion-Biotech GmbH
  • 14. Spark Therapeutics, Inc. by F. Hoffmann-La Roche Ltd.
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. VIRAL VECTORS MARKET RESEARCH PROCESS
  • FIGURE 2. VIRAL VECTORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VIRAL VECTORS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VIRAL VECTORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VIRAL VECTORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VIRAL VECTORS MARKET DYNAMICS
  • TABLE 7. GLOBAL VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENO-ASSOCIATED VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VIRAL VECTORS MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VIRAL VECTORS MARKET SIZE, BY RETROVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY CANCERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VIRAL VECTORS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VIRAL VECTORS MARKET SIZE, BY VACCINOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VIRAL VECTORS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VIRAL VECTORS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES VIRAL VECTORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM VIRAL VECTORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. VIRAL VECTORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. VIRAL VECTORS MARKET, FPNV POSITIONING MATRIX, 2023